Menopausal
Disorders Drug Development Research Report provides an overview of the
pipeline landscape for menopausal disorders. It provides comprehensive
information on the therapeutics under development and key players involved in
therapeutic development for postmenopausal osteoporosis, vaginal atrophy and
vasomotor symptoms of menopause, and features dormant and discontinued
products.
Postmenopausal
osteoporosis is the most common form of osteoporosis. It affects many women
after menopause. Symptoms include back pain, loss of height, or spinal deformities
such as stooped posture. Risk factors include age, gender, family history, bone
structure and body weight. There are 20 products in development for this
indication.
Vaginal
atrophy is thinning, drying and inflammation of the vaginal walls due to the
body having less estrogen. Signs and symptoms include vaginal dryness, vaginal
discharge, genital itching, burning with urination, and urgency with urination,
urinary tract infections and urinary incontinence.
Risk
factor includes smoking. Smoking impairs blood circulation, depriving the
vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is
decreased or restricted. There are five products in development for this
indication.
Vasomotor
symptoms of menopause include hot flashes or night sweats that result from
sudden opening of the blood vessels close to the skin, usually due to hormonal
fluctuations in menopause and perimenopause. These symptoms are caused due to
some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis,
anxiety and panic disorders, obesity, hormonally active tumors, chronic
infections and neurological disorders. There are 12 products in development for
this indication.
Molecular
targets acted on by products in development for menopausal disorders include
tumor necrosis factor ligand superfamily member 11, parathyroid hormone
receptor and progesterone receptor. Companies operating in this pipeline space
include Amgen, TherapeuticsMD and Ipsen.
The report also includes the
following details:-
-
Which companies are the most active within each pipeline?
-
Which pharmaceutical approaches are the most prominent at each stage of the
pipeline and within each indication?
-
To what extent do universities and institutions play a role within this
pipeline, compared to pharmaceutical companies?
-
What are the most important R&D milestones and data publications to have
happened in this disease area?
-
Understand the overall pipeline, with an at-a-glance overview of all products
in therapeutic development for each indication
- Assess the products in
development in granular detail, with an up-to-date overview of each individual
pipeline program in each indication and a comprehensive picture of recent
updates and milestones for each
-
Analyze the companies, institutions and universities currently operating in the
pipeline and the products being fielded by each of these
-
Understand the composition of the pipeline in terms of molecule type, molecular
target, mechanism of action and route of administration
To know more, click on the link
below:
Contact Us:
Ken Research
Ankur Gupta,
Head Marketing & Communications
+91-9015378249
